Want to find out about the disease modifying drugs (DMDs) available to treat multiple sclerosis (MS)? MS Decisions is a guide to the DMDs approved for treating relapsing remitting MS in the UK.

Answers to some of the most commonly asked questions about disease modifying drugs (DMDs) for multiple sclerosis (MS).

Lemtrada (alemtuzumab) is a disease modifying drug treatment for relapsing remitting MS. You take Lemtrada as an intravenous infusion (drip) in two treatment courses, twelve months apart.

Tysabri (natalizumab) is a disease modifying drug treatment for relapsing remitting MS. You take Tysabri as an intravenous infusion (drip) once every four weeks.

Tyruko (natalizumab) is a disease modifying drug treatment for relapsing remitting MS. It is a biosimilar alternative to Tysabri, taken as an intravenous infusion every four weeks.

Zeposia (ozanimod) is a disease modifying drug treatment for active relapsing remitting MS. You take Zeposia as a pill once a day.

Aubagio (teriflunomide) is a disease modifying drug treatment for relapsing remitting multiple sclerosis. You take Aubagio as a pill once a day.

Dizziness or lightheadness is a common symptom of multiple sclerosis. If the sensation is more severe, it is referred to as vertigo. There are a number of approaches to managing dizziness including medication and exercise programmes.

Each NHS trust in England has a Patient Advice and Liaison Service (PALS). PALS offers confidential advice, support and information on health related issues and acts as a point of contact for patients, their families and their carers.